PACB [NASD]
Pacific Biosciences of California, Inc.
Index- P/E- EPS (ttm)-0.81 Insider Own0.70% Shs Outstand222.29M Perf Week-3.94%
Market Cap1.08B Forward P/E- EPS next Y-1.24 Insider Trans-5.04% Shs Float221.69M Perf Month-15.89%
Income-175.30M PEG- EPS next Q-0.33 Inst Own91.50% Short Float14.87% Perf Quarter-51.09%
Sales134.70M P/S7.99 EPS this Y-628.30% Inst Trans4.68% Short Ratio5.26 Perf Half Y-77.72%
Book/sh3.30 P/B1.70 EPS next Y-30.60% ROA-9.70% Target Price16.80 Perf Year-78.06%
Cash/sh5.02 P/C1.12 EPS next 5Y-1.00% ROE-26.70% 52W Range4.51 - 36.36 Perf YTD-72.58%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-10.00% 52W High-84.57% Beta1.49
Dividend %- Quick Ratio16.40 Sales past 5Y7.50% Gross Margin44.60% 52W Low24.39% ATR0.68
Employees728 Current Ratio16.90 Sales Q/Q14.50% Oper. Margin- RSI (14)41.40 Volatility10.28% 12.27%
OptionableYes Debt/Eq1.22 EPS Q/Q18.30% Profit Margin- Rel Volume1.28 Prev Close5.60
ShortableYes LT Debt/Eq1.22 EarningsMay 04 AMC Payout- Avg Volume6.26M Price5.61
Recom2.20 SMA20-7.95% SMA50-29.10% SMA200-69.30% Volume8,024,171 Change0.18%
Jan-21-22Resumed Cantor Fitzgerald Overweight $62 → $31
Jan-06-22Resumed Piper Sandler Neutral $20
Oct-15-21Resumed Cowen Market Perform $30
Sep-27-21Initiated Canaccord Genuity Buy $45
Feb-11-21Upgrade Piper Sandler Neutral → Overweight $20 → $52
Nov-03-20Downgrade Piper Sandler Overweight → Neutral $12
Oct-02-20Upgrade JP Morgan Neutral → Overweight $15
Sep-09-20Initiated Morgan Stanley Equal-Weight $7
Jun-02-20Resumed Cantor Fitzgerald Overweight $5
Mar-09-20Resumed Cantor Fitzgerald Overweight $5
Oct-15-19Upgrade Piper Jaffray Neutral → Overweight $8
Apr-02-19Downgrade Stephens Overweight → Equal-Weight $4.50 → $8
Oct-19-18Initiated Cowen Outperform
Nov-03-17Downgrade First Analysis Sec Overweight → Equal-Weight $4
Sep-28-17Downgrade CL King Buy → Neutral
Nov-03-16Reiterated Cantor Fitzgerald Buy $18 → $15
Jun-27-16Initiated CL King Buy
Apr-15-16Initiated First Analysis Sec Overweight $11
Feb-04-16Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16Reiterated Cantor Fitzgerald Buy $11 → $18
May-08-22 07:00PM  
May-05-22 04:10PM  
10:54AM  
09:50AM  
May-04-22 06:05PM  
04:03PM  
Apr-27-22 03:03PM  
Apr-21-22 09:16AM  
09:10AM  
09:00AM  
Apr-20-22 04:02PM  
Apr-12-22 08:25AM  
Apr-04-22 09:00AM  
Mar-31-22 02:00PM  
Mar-23-22 09:00AM  
Mar-18-22 11:00AM  
10:08AM  
Mar-17-22 11:30AM  
Mar-07-22 10:57AM  
Feb-28-22 09:00AM  
08:59AM  
Feb-25-22 05:00PM  
Feb-23-22 09:54AM  
09:00AM  
Feb-16-22 09:53AM  
09:00AM  
06:03AM  
Feb-15-22 05:55PM  
04:05PM  
Feb-09-22 04:05PM  
Feb-08-22 08:53AM  
Feb-02-22 03:01PM  
Feb-01-22 04:05PM  
11:22AM  
Jan-18-22 08:56AM  
Jan-17-22 09:16AM  
Jan-14-22 04:05PM  
Jan-13-22 07:00AM  
Jan-12-22 09:35AM  
Jan-11-22 01:13PM  
09:06AM  
07:15AM  
07:10AM  
07:05AM  
07:00AM  
Jan-10-22 10:17AM  
Jan-07-22 09:00AM  
Jan-06-22 11:58AM  
09:00AM  
Jan-05-22 09:00AM  
Jan-04-22 04:05PM  
Dec-29-21 11:05AM  
Dec-28-21 09:00AM  
Dec-17-21 09:04AM  
Dec-12-21 10:49PM  
Dec-10-21 08:20AM  
Dec-09-21 12:32PM  
Dec-07-21 09:00AM  
Dec-03-21 05:00PM  
Nov-30-21 09:00AM  
Nov-26-21 03:58PM  
Nov-22-21 05:37PM  
07:40AM  
07:00AM  
Nov-19-21 05:00PM  
Nov-18-21 10:29AM  
09:00AM  
Nov-16-21 09:00AM  
Nov-11-21 04:05PM  
Nov-03-21 08:00PM  
08:34AM  
04:01AM  
Nov-02-21 05:55PM  
04:05PM  
04:03PM  
Oct-27-21 06:17AM  
Oct-26-21 03:02PM  
Oct-19-21 04:05PM  
Oct-18-21 09:02AM  
Oct-11-21 12:30PM  
Sep-29-21 11:05AM  
Sep-27-21 09:00AM  
Sep-24-21 04:05PM  
Sep-21-21 09:18AM  
Sep-20-21 04:05PM  
Sep-03-21 09:00AM  
Sep-02-21 11:31AM  
Aug-23-21 10:11AM  
Aug-09-21 08:00AM  
Aug-05-21 12:30PM  
Aug-04-21 11:26AM  
09:31AM  
06:52AM  
06:45AM  
03:18AM  
Aug-03-21 05:25PM  
04:05PM  
08:00AM  
Jul-28-21 04:05PM  
Jul-27-21 03:03PM  
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farmer MicheleSee RemarksMay 18Sale5.553,57319,81960,354May 20 03:31 PM
Kim Susan G.Chief Financial OfficerFeb 17Sale11.061,06211,746134,966Feb 22 04:47 PM
HENRY CHRISTIAN OPresident & CEOFeb 17Sale11.092,12223,533672,358Feb 22 04:44 PM
ORDONEZ KATHYDirectorFeb 16Sale11.503,28037,72018,595Feb 17 08:11 PM
MOHR MARSHALLDirectorJan 14Option Exercise3.5725,00089,25025,000Jan 19 06:54 PM
Van Oene MarkChief Operating OfficerJan 11Sale14.2341,480590,260293,520Jan 13 06:15 PM
Fromen PeterChief Commercial OfficerJan 11Sale14.3019,720281,996140,280Jan 13 06:13 PM
Kim Susan G.Chief Financial OfficerSep 29Sale25.7520,272522,004136,028Oct 01 05:31 PM
HENRY CHRISTIAN OPresident & CEOSep 16Sale26.9190,5202,435,893674,480Sep 17 04:53 PM
Ericson William W.DirectorMay 25Option Exercise4.7537,500178,00037,500May 26 08:50 PM
Ericson William W.DirectorMay 25Sale25.8937,500971,0580May 26 08:50 PM